CN114908036A - Application of integrin alpha 5 beta 1 receptor in preparation of antibacterial exosomes - Google Patents
Application of integrin alpha 5 beta 1 receptor in preparation of antibacterial exosomes Download PDFInfo
- Publication number
- CN114908036A CN114908036A CN202210492186.1A CN202210492186A CN114908036A CN 114908036 A CN114908036 A CN 114908036A CN 202210492186 A CN202210492186 A CN 202210492186A CN 114908036 A CN114908036 A CN 114908036A
- Authority
- CN
- China
- Prior art keywords
- receptor
- antibacterial
- beta
- exosomes
- integrin alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 51
- 108010042918 Integrin alpha5beta1 Proteins 0.000 title claims abstract description 34
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 28
- 210000004027 cell Anatomy 0.000 claims abstract description 22
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 18
- 239000000304 virulence factor Substances 0.000 claims abstract description 12
- 230000007923 virulence factor Effects 0.000 claims abstract description 12
- 230000000694 effects Effects 0.000 claims abstract description 9
- 230000004936 stimulating effect Effects 0.000 claims abstract description 5
- 102000005962 receptors Human genes 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- 238000003306 harvesting Methods 0.000 claims description 3
- 230000007123 defense Effects 0.000 abstract description 12
- 244000052769 pathogen Species 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 17
- 230000001717 pathogenic effect Effects 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 3
- 108090000794 Streptopain Proteins 0.000 description 3
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000007124 immune defense Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102100032817 Integrin alpha-5 Human genes 0.000 description 2
- 108010041014 Integrin alpha5 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102000008228 Toll-like receptor 2 Human genes 0.000 description 1
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of an integrin alpha 5 beta 1 receptor in preparation of an antibacterial exosome, wherein the exosome secreted by the integrin alpha 5 beta 1 receptor on the surface of an epithelial cell when the integrin alpha 5 beta 1 receptor is combined by pathogenic bacteria has an antibacterial effect, so that a host has the effect of combining virulence factors of extracellular pathogens to protect surrounding uninfected cells. The antibacterial exosomes of the integrin α 5 β 1 receptor are: collecting exosomes produced by heat-inactivated GAS stimulating normal epithelial cells and epithelial cells knocked-down for integrin alpha 5 beta 1; the technical scheme disclosed by the invention can enhance the defense capacity of a human body by injecting the artificial exosome into the body to absorb pathogenic bacteria virulence factors or increasing the production of exosomes.
Description
Technical Field
The invention relates to application of integrin alpha 5 beta 1 receptor mediated epithelial cells in forming antibacterial exosomes, and relates to the technical field of immune defense.
Background
In the process of pathogen and host gaming, the sensing ability of host cells to pathogens through surface receptors is a key factor for determining whether host cells can establish effective innate defense first. After the host cell senses the bacteria, the mechanism by which the host cell resists bacterial infection is an important breakthrough for finding new antibacterial components or drug targets.
Early studies found that cell surface receptor integrin α 5 β 1 can induce autophagy that can clear Group A Streptococci (GAS) in epithelial cells; exosomes (Exosomes) research is mostly focused in the field of tumors, but researches on Exosomes and pathogen infection also obtain some instructive results in recent years, but how to determine the composition and functions of Exosomes in the pathogen infection process and how host cells mediate the formation process of infection-related Exosomes is an important problem to be solved by Exosomes in the pathogen-host cell research work.
In our previous experiments, it was also found that exosomes induced by infection of epithelial cells by Group A Streptococcus (GAS) have the ability to bind streptopyretogenic exotoxin (SpeB, an important virulence factor secreted by GAS, capable of degrading host extracellular matrix, immunoglobulin and complement components, destroying host defense system, escaping immune clearance, assisting in GAS diffusion at the initial infection site and invading host deep tissues), so that it cannot bind to epithelial cell membrane to cause destruction, thus greatly reducing the pathogenicity of GAS. We speculate that this antibiotic exosome, termed "decoy", binds to the intracellular free GAS virulence factor SpeB, rendering it inactive, thereby exerting an antibacterial effect and protecting the host cell before the SpeB acts on the cell.
Exosomes closely related to pathogenic microorganism infection may play a role in protecting normal host cells and preventing infection spread when pathogenic microorganisms fail to contact cells. The exosome effectively protects the mouse from being attacked by GAS, and the survival rate of the mouse is improved. And (4) prompting by a result: when infection occurs, host cells secrete an exosome with antibacterial capacity, and a reaction mode that the cells secrete antibacterial substances can be caused by contacting with corresponding receptors on the surface of host cell membranes without pathogenic bacteria invading cells, so that time is taken for establishing rapid defense for the hosts.
It is contemplated that TLR2 and TLR4 are the major pattern recognition receptors for GAS infection, and that TLRs can induce exosome formation upon infection or ligand stimulation. Next, we used siRNA to knock down TLR2 and TLR4 receptors, and found that heat inactivated GAS can also induce a large amount of exosomes to produce and still have antibacterial ability, and the number of intracellular bacteria has no significant difference compared with the no-knock-out TLR2 and TLR4 control group, indicating that TLR2 and TLR4 are not GAS to induce the main receptor of exosomes with antibacterial ability. Integrins are transmembrane receptors that mediate the link between cells and their environment (e.g., extracellular matrix, ECM), and are a major family of cell surface receptors. Most cell surfaces express more than one integrin, which plays a key role in a variety of vital activities. Among them, integrin α 5 β 1 mediates invasion of various intracellular or extracellular bacteria upon infection with pathogenic bacteria. Is integrin α 5 β 1 a key receptor for GAS invasion into epithelial or endothelial cells, and in addition to being a receptor that we have previously discovered to mediate autophagy, also mediates the formation of antibacterial exosomes? At present, no relevant report is found.
Disclosure of Invention
The invention aims to provide application of integrin alpha 5 beta 1 receptor in preparation of antibacterial exosome, wherein the exosome secreted by the integrin alpha 5 beta 1 receptor on the surface of epithelial cells when being combined with pathogenic bacteria components has an antibacterial effect, so that a host has the effect of combining virulence factors of extracellular pathogenic bacteria and protects surrounding uninfected cells.
In order to achieve the technical purpose and achieve the technical effect, the invention is realized by the following technical scheme:
application of integrin alpha 5 beta 1 receptor in preparation of antibacterial exosomes.
Furthermore, the exosome secreted by the epithelial cell surface integrin alpha 5 beta 1 receptor when being bound by pathogenic bacteria components has an antibacterial effect, so that a host has the effect of binding with an extracellular pathogenic bacteria virulence factor and protects surrounding uninfected cells.
Further, the preparation method of the antibacterial exosome of the integrin alpha 5 beta 1 receptor comprises the following steps: harvesting exosomes produced by heat-inactivated GAS stimulating normal epithelial cells and epithelial cells that have been knocked down for integrin α 5 β 1.
It is another object of the present invention to provide an antibacterial exosome obtained by collecting heat-inactivated GAS-stimulated normal epithelial cells and integrin alpha 5 beta 1-knocked-down epithelial cells.
The invention has the beneficial effects that:
the invention aims to provide application of integrin alpha 5 beta 1 receptor in preparation of antibacterial exosome, wherein the exosome secreted by the integrin alpha 5 beta 1 receptor on the surface of epithelial cells when being combined with pathogenic bacteria components has an antibacterial effect, so that a host has the effect of combining virulence factors of extracellular pathogenic bacteria and protects surrounding uninfected cells.
The invention discloses a new mode of integrin alpha 5 beta 1 receptor mediated epithelial cell innate defense; this finding not only increases the knowledge of mammals against infections, but also suggests new strategies for enhancing the immune system, such as enhancing the body's defenses by injecting artificial exosomes into the body to take up pathogenic virulence factors or by increasing exosome production. This mode of action, which is capable of performing innate defense functions at the earliest stages of pathogenic infection, also provides sufficient time for other widely recognized immune defense mechanisms (e.g., pathogenic bacteria activating T cells or producing antibodies), and the host protects against infection through a layered defense function, thereby maintaining a healthy state.
Of course, it is not necessary for any product in which the invention is practiced to achieve all of the above-described advantages at the same time.
Detailed Description
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the present invention will be described in detail with reference to the embodiments.
Example 1
Application of integrin alpha 5 beta 1 receptor in preparation of antibacterial exosomes.
The epithelial cell surface integrin alpha 5 beta 1 receptor has an antibacterial effect on an exosome secreted by the receptor when the receptor is combined by pathogenic bacteria components, so that a host has the effect of combining an extracellular pathogenic bacteria virulence factor and protects surrounding uninfected cells.
Example 2
The preparation method of the antibacterial exosome of the integrin alpha 5 beta 1 receptor comprises the following steps:
harvesting exosomes produced by heat-inactivated GAS stimulating normal epithelial cells and epithelial cells that have been knocked down for integrin α 5 β 1.
Example 3
An antibacterial exosome obtained by collecting heat-inactivated GAS-stimulated normal epithelial cells and integrin alpha 5 beta 1-knocked-down epithelial cells.
The invention aims to provide application of integrin alpha 5 beta 1 receptor in preparation of antibacterial exosome, wherein the exosome secreted by the integrin alpha 5 beta 1 receptor on the surface of epithelial cells when being combined with pathogenic bacteria components has an antibacterial effect, so that a host has the effect of combining virulence factors of extracellular pathogenic bacteria and protects surrounding uninfected cells.
The invention discloses a new mode of integrin alpha 5 beta 1 receptor mediated epithelial cell innate defense; this finding not only increases the knowledge of mammals against infections, but also suggests new strategies for enhancing the immune system, such as enhancing the body's defenses by injecting artificial exosomes into the body to take up pathogenic virulence factors or by increasing exosome production. This mode of action, which is capable of performing innate defense functions at the earliest stages of pathogenic infection, also provides sufficient time for other widely recognized immune defense mechanisms (e.g., pathogenic bacteria activating T cells or producing antibodies), and the host protects against infection through a layered defense function, thereby maintaining a healthy state.
In the description herein, references to the description of "one embodiment," "an example," "a specific example" or the like are intended to mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
The preferred embodiments of the invention disclosed above are intended to be illustrative only. The preferred embodiments are not intended to be exhaustive or to limit the invention to the precise embodiments disclosed. Obviously, many modifications and variations are possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and the practical application, to thereby enable others skilled in the art to best utilize the invention. The invention is limited only by the claims and their full scope and equivalents.
Claims (4)
1. Application of integrin alpha 5 beta 1 receptor in preparation of antibacterial exosomes.
2. Use of the integrin α 5 β 1 receptor of claim 1 for the preparation of antibacterial exosomes, wherein: the epithelial cell surface integrin alpha 5 beta 1 receptor has an antibacterial effect on an exosome secreted by the receptor when the receptor is combined by pathogenic bacteria components, so that a host has the effect of combining an extracellular pathogenic bacteria virulence factor and protects surrounding uninfected cells.
3. Use of the integrin α 5 β 1 receptor of claim 2 for the preparation of antibacterial exosomes, wherein: the preparation method of the antibacterial exosome of the integrin alpha 5 beta 1 receptor comprises the following steps: harvesting exosomes produced by heat-inactivated GAS stimulating normal epithelial cells and epithelial cells that have been knocked down for integrin α 5 β 1.
4. An antibacterial exosome, characterized by: stimulating normal epithelial cells by collecting heat-inactivated GAS and knocking down integrin alpha 5 beta 1 epithelial cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210492186.1A CN114908036A (en) | 2022-05-07 | 2022-05-07 | Application of integrin alpha 5 beta 1 receptor in preparation of antibacterial exosomes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210492186.1A CN114908036A (en) | 2022-05-07 | 2022-05-07 | Application of integrin alpha 5 beta 1 receptor in preparation of antibacterial exosomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114908036A true CN114908036A (en) | 2022-08-16 |
Family
ID=82767066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210492186.1A Pending CN114908036A (en) | 2022-05-07 | 2022-05-07 | Application of integrin alpha 5 beta 1 receptor in preparation of antibacterial exosomes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114908036A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109666695A (en) * | 2018-12-26 | 2019-04-23 | 上海交通大学医学院附属第九人民医院 | A kind of excretion body carrier and its preparation method and application of targeted integration element α v β 3 |
| CN110613728A (en) * | 2017-12-11 | 2019-12-27 | 浙江大学 | Application of NK cell exosome hsa-miR-9773 in antibiosis |
| KR20210049014A (en) * | 2019-10-24 | 2021-05-04 | 가톨릭대학교 산학협력단 | COMPOSITION INCLUDING EXOSOME CONTAINING INTEGRIN α6 AND αX FOR PREVENTING OR TREATING GASTRIC CANCER |
-
2022
- 2022-05-07 CN CN202210492186.1A patent/CN114908036A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110613728A (en) * | 2017-12-11 | 2019-12-27 | 浙江大学 | Application of NK cell exosome hsa-miR-9773 in antibiosis |
| CN109666695A (en) * | 2018-12-26 | 2019-04-23 | 上海交通大学医学院附属第九人民医院 | A kind of excretion body carrier and its preparation method and application of targeted integration element α v β 3 |
| KR20210049014A (en) * | 2019-10-24 | 2021-05-04 | 가톨릭대학교 산학협력단 | COMPOSITION INCLUDING EXOSOME CONTAINING INTEGRIN α6 AND αX FOR PREVENTING OR TREATING GASTRIC CANCER |
Non-Patent Citations (3)
| Title |
|---|
| JIACHAO WANG等: "Integrin α5β1, as a Receptor of Fibronectin, Binds the FbaA Protein of Group A Streptococcus To Initiate Autophagy during Infection", 《MBIO .》, vol. 11, no. 3, pages 00771 - 20 * |
| 李凯;郑鹏远;刘志强;陈东晖;: "肠上皮细胞来源的整合素αVβ6对肠道树突状细胞TGF-β1表达的影响", 世界华人消化杂志, no. 17, pages 1642 - 1648 * |
| 王家超等: "整合素α5β1受体介导具有抗菌作用外泌体产生的机制研究", 《第十四届全国免疫学学术大会论文摘要汇编 中国免疫学会》, pages 192 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brandt et al. | Innate immunity to Staphylococcus aureus: evolving paradigms in soft tissue and invasive infections | |
| Ramírez Granillo et al. | Antibiosis interaction of Staphylococccus aureus on Aspergillus fumigatus assessed in vitro by mixed biofilm formation | |
| Steere et al. | Lyme borreliosis | |
| Buchanan et al. | DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps | |
| Jarchum et al. | Critical role for MyD88-mediated neutrophil recruitment during Clostridium difficile colitis | |
| Nasser et al. | A comprehensive review of bacterial osteomyelitis with emphasis on Staphylococcus aureus | |
| Harms et al. | Intruders below the radar: molecular pathogenesis of Bartonella spp | |
| Rossoni et al. | Clinical strains of Lactobacillus reduce the filamentation of Candida albicans and protect Galleria mellonella against experimental candidiasis | |
| Narváez-Barragán et al. | Expansin-like Exl1 from Pectobacterium is a virulence factor required for host infection, and induces a defence plant response involving ROS, and jasmonate, ethylene and salicylic acid signalling pathways in Arabidopsis thaliana | |
| CN104073440B (en) | One strain paecilomyces fumosoroseus and application thereof | |
| Hill | A staphylococcal aggressin | |
| Schubert et al. | The Yersinia type III secretion system as a tool for studying cytosolic innate immune surveillance | |
| CN114908036A (en) | Application of integrin alpha 5 beta 1 receptor in preparation of antibacterial exosomes | |
| Yang et al. | The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model | |
| EP2032169A2 (en) | Methods and compositions for the treatment and prevention of staphylococcus aureus infections through interference with opuc operon interaction with trap | |
| CN114246876B (en) | Application of sennoside A in preparation of preparation for resisting pseudomonas aeruginosa infection | |
| CN101843631B (en) | Application of baicalin in resisting and preventing bacterial infection | |
| Curlango-Rivera et al. | Signals controlling extracellular trap formation in plant and animal immune responses | |
| Liu et al. | Research Progress on the pathogenic mechanism of Streptococcus suis 2 | |
| Panayidou et al. | Pseudomonas aeruginosa | |
| CN108125987A (en) | A kind of method for building staphylococcus aureus subcutaneous infection model | |
| Gowda et al. | Human dental caries pathogen Streptococcus mutans affect chitin synthesis and that restored by antibiotics in the silkworm, Bombyx mori | |
| Visai et al. | Staphylococcus biofilm components as targets for vaccines and drugs | |
| Singh et al. | Molecular mechanism of biofilm formation of pathogenic microorganisms and their role in host pathogen interaction | |
| Al-Mathkhury et al. | Histopathological effects of S. xylosus peptidoglycan in comparison to E. coli lipopolysaccharide in the urinary tract of mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |